Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn. MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder. More information...
According to PR-model, definiumtx.com is ranked 1,803,472nd in multilingual Wikipedia, in particular this website is ranked 962,008th in English Wikipedia.
The website is placed before pinchas-steinberg.com and after nepaldeep.com in the BestRef global ranking of the most important sources of Wikipedia.
